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SUMMARY
Parasitic protozoa comprise diverse aetiological agents responsible for important diseases in humans and animals including
sleeping sickness, Chagas disease, leishmaniasis, malaria, toxoplasmosis and others. They are major causes of mortality and
morbidity in tropical and subtropical countries, and are also responsible for important economic losses. However, up to
now, for most of these parasitic diseases, effective vaccines are lacking and the approved chemotherapeutic compounds
present high toxicity, increasing resistance, limited efficacy and require long periods of treatment. Many of these parasitic
illnesses predominantly affect low-income populations of developing countries for which new pharmaceutical alternatives
are urgently needed. Thus, very low research funding is available. Amidine-containing compounds such as pentamidine are
DNA minor groove binders with a broad spectrum of activities against human and veterinary pathogens. Due to their
promising microbicidal activity but their rather poor bioavailability and high toxicity, many analogues and derivatives,
including pro-drugs, have been synthesized and screened in vitro and in vivo in order to improve their selectivity and
pharmacological properties. This review summarizes the knowledge on amidines and analogues with respect to their
synthesis, pharmacological profile, mechanistic and biological effects upon a range of intracellular protozoan parasites. The
bulk of these data may contribute to the future design and structure optimization of new aromatic dicationic compounds as
novel antiparasitic drug candidates.
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INTRODUCTION
Protozoan parasites cause a wide range of infectious
diseases of medical and veterinary importance, and
thus represent a major economic burden worldwide.
Prevention and chemotherapy are two routes that
are tracked to combat parasitic diseases. However,
despite the fact that considerable efforts have been
undertaken, not a single vaccine against a parasitic
infection in humans has been marketed to date, and
only a few have been commercialized for veterinary
application, most of them live-attenuated vaccines.
Thus, chemotherapeutic treatment still remains the
sole option. Most drugs that are currently in use to
combat parasitic infections were discovered decades
ago, and development of resistance poses a major
threat (Mäser et al. 2012). Chemotherapy is a viable
choice, if potent, safe and inexpensive drugs are
made available, which are also easily administered,
preferentially interfering in more than just one stage
of the parasite life cycle and exhibiting selective
toxicity (Delves et al. 2012). Thus, candidate
compounds must be thoroughly characterized with
regard to their mechanisms of action and potential
targets.
Intracellular protozoan parasites, especially the
trypanosomatids (e.g. Leishmania, Trypanosoma
cruzi) and the apicomplexans (e.g. Plasmodium and
Toxoplasma among others), have a significant socio-
economic impact worldwide. Their pathogenesis is
related to the intracellular stages of their life cycle.
This means that any compound targeted to kill these
parasites must first cross the host cell membrane,
then the parasitophorous vacuole membrane (rele-
vant for most, but not all species), followed by the
parasite plasmalemma, and finally also membranes of
the organelle containing the relevant target(s). If the
pathogen infects the CNS, the blood–brain barrier
represents a further obstacle. Not surprisingly, the
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treatment options for diseases caused by these para-
sites are still limited, despite recent advances in some
areas (Mäser et al. 2012).
In this review, we will focus on the design,
synthesis, pharmacology and the mechanisms of
action of amidine compounds and analogues (essen-
tially derivatives of the broad-spectrum drug penta-
midine) upon a range of intracellular protozoan
parasites causing important diseases in animals and
man, including Leishmania, T. cruzi, Plasmodium,
Babesia, Toxoplasma, Neospora and Besnoitia.
DESIGN AND SYNTHESIS
Investigations into the antiprotozoan activity of
classical aromatic diamidines (dicationic molecules –
Figs. 1–6) began over 7 decades ago with the
pioneering work of Warrington Yorke (King et al.
1937). The early work led to the discovery that
pentamidine (Fig. 1) and other aromatic diamidines
were effective against human African trypano-
somes (HAT) and some species of Leishmania
(Ashley et al. 1942). Despite decades of extensive
investigation into this class of compounds, pentami-
dine remains the only diamidine with significant
clinical value and it is still used to treat antimony-
resistant leishmaniasis, early stage Trypanosoma
brucei gambiense HAT and Pneumocystis jiroveci
infections (formerly Pneumocystis carinii) (Sands
et al. 1985; Goa and Campoli-Richards, 1987;
Barrett et al. 2003, 2007; Werbovetz, 2006; Singh
et al. 2012). A limitation of pentamidine (and most
diamidines) is that it must be administered parent-
erally due to its poor bioavailability attributable, in
large part, to the high pKa of the amidine functional
group (10–12).
In the last decade, pafuramidine (DB289, Fig. 3),
an orally effective pro-drug of the diamidine furami-
dine (Fig. 1), was found to be effective against first-
stage HAT in a Phase III trial. Unfortunately, in a
concurrent extended safety trial (Phase I) delayed
renal toxicity was observed and the development of
DB 289 was discontinued (Paine et al. 2010). Later
(as will be detailed in the following sections), another
class of amidines, initially described as ‘reversed
amidines’ but now referred to as arylimidamides
(Figs 1, 4 and 5), demonstrated high potency against
several parasites like T. cruzi, Leishmania sp.
(Stephens et al. 2003; Wang et al. 2010; Zhu et al.
2012), Neospora caninum (Debache et al. 2011;
Schorer et al. 2012), Besnoitia besnoiti (Cortes et al.
2011) and Echinococcus multilocularis (Stadelmann
et al. 2011). Arylimidamides (AIAs) have lower pKa
values (7–8) than classical aromatic amidines and
therefore generally exhibit better bioavailability
(Wang et al. 2010). The mode of action of both
classes of amidines remains to be rigorously deter-
mined (as will be further discussed in see section
‘Mechanisms of antiparasitic action’). The two
strands of the DNA double helix wrapped around
each other creates two helical grooves, a wider, the
major groove and a narrow one, the minor groove.
The effectiveness of classical aromatic diamidines in
recognizing the minor groove (space between the
strands) of AT-rich sequences of DNA has led to a
useful strategy for the design of new potential
antiparasitic agents (Tidwell and Boykin 2003;
Wilson et al. 2005, 2008; Nguyen et al. 2007). The
beginning of a design paradigm for the targeting of
the minor groove of DNA was clearly presented as
early as the mid 1980s (Goodsell and Dickerson,
1986). Based on crystal structure data for known
minor-groove binders such as netropsin, distamycin,
Hoechst 33 258 and related compounds, these
authors concluded that the shape of the small
molecule should be isohelical with the groove to
which it was binding. Furthermore, the hydrogen
bond acceptor and donors needed to be properly
spaced to optimize the hydrogen-bonding inter-
actions. Using these ideas J. W. Lown and
co-workers developed a number of libraries of
lexitropsin DNA minor-groove binders that were
quite effective (Lown, 1994). These isohelical design
ideas were expanded to aromatic diamidine ana-
logues, including pentamidine, and were correlated
with estimated radii of curvature for the small
molecules (Cory et al. 1992). Thus for a number of
years it was believed that a crescent-shaped small
molecule was necessary to achieve higher binding
affinity (Tidwell and Boykin, 2003). The near linear
potent antitrypanosomal compound CGP 40215A
(Fig. 1) was found to be a very strong minor-groove
binder and the structure for a co-crystal with d
(CGCGAATTCGCG)2 showed that 2 water mol-
ecules participate in an indirect hydrogen bond
between one of the amidine groups and a thymine
carbonyl group (Nguyen et al. 2002, 2004). A study
of the antitrypanosomal isomeric dicationic bi-
phenylbenzimidazoles DB911 and DB921 (Fig. 1)
provided another case to evaluate the necessity of
small molecule-DNA groove shape complementari-
ties (Ismail et al. 2004, 2005;Miao et al. 2005). In this
pair DB911 has the classical crescent shape associated
with the DNA minor groove whereas DB921 is a
near-linear molecule, therefore it was a surprise
that the DNA binding affinity to an A/T site for
DB921 was 10-fold higher than that of DB911
(Miao et al. 2005). The structure of a DB921-d
(CGCGAATTCGCG)2 co-crystal clearly showed
that 1 water molecule forms a hydrogen bond array
between the benzamidine group of DB921 and an
adenine N atom (Miao et al. 2005). These examples
show that water can mediate the interaction between
linear dications and the DNA minor groove thus
in effect providing an isohelical complex. Since
water can serve as hydrogen bond isohelical
mediators for linear dicationic molecules, such
interactions should be taken into account in the
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design of potential minor-groove binders. For a more
detailed treatment of this subject see the review by
Nguyen et al. (2007).
Aromatic diamidines are usually prepared from
their corresponding bis-nitriles. In this review
3 major methods for achieving this conversion will
be presented along with illustrations from the
literature. The most venerable method for the nitrile
to amidine conversion is known as the Pinner amidine
synthesis which was first described by Pinner in 1877
(Pinner and Klein, 1877). This method, which is
arguably the most widely used, has been reviewed by
several authors (Shriner and Neumann, 1944; Roger
and Neilson, 1961; Eloy and Lenaers, 1962; Aly and
Nour-El-Din, 2008). Scheme 1 illustrates this 2-step
process which was used in the synthesis of furamidine
(Fig. 1) (Das and Boykin, 1977). The first step
involves acid-catalysed addition of ethanol to the
nitrile groups to form an imidate ester. The second
step results in the formation of the amidine by the
addition of ammonia or a wide array of amines; the
latter gives this approach great versatility by allowing
the generation of libraries of N-substituted amidines
(Boykin et al. 1995). A major limitation of this
method is that water must be rigorously excluded. A
further complication is that aromatic bis-nitriles are
frequently quite insoluble, which necessitates large
volumes of solvent or long reaction times, either of
which increase the possibility for exposure to water.
The second important method involves the
intermediacy of amidoximes and is outlined in
Scheme 2 (Judkins et al. 1996). This methodology
was employed for the synthesis of highly active
imidazo[1,2-a]pyridines (Ismail et al. 2004) and
has been effectively employed in several other
systems (Ismail et al. 2006, 2008, 2011). This process
formally involves 3 steps; however, in practice the
acetoxy analogue is not isolated, so functionally it is a
2-step process. This method has the advantage that
Fig. 2. Fluorescent microscopy of aromatic diamidine
DB1582 (A) and DB1651 (B) staining of bloodstream
trypomastigotes (A) and intracellular forms (B) of
T. cruzi (Y strain). Parasites and infected-cardiac cell
cultures were incubated for 60min with10 μg mL−1
DB1582 and DB1651. Note the dicationic compound in
the parasite KDNA (arrow), nuclei (star) and within
several non-DNA-containing organelles (arrowhead)
distributed within the cytoplasm of intracellular
amastigotes (acidocalcisomes-like structures). See host
cell nuclei also labelled (N).
Fig. 1. Chemical structures of aromatic diamidines and arylimidamides.
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rigorous water exclusion is not necessary. Unlike the
Pinner process, N-substituted amidines cannot be
made using this sequence. The presence of functional
groups which can be reduced or cleaved under
catalytic hydrogenation conditions and compounds
that include sulphur-containing groups, which may
poison the catalyst, reduce the flexibility of this
method.
The third important method is clearly the most
elegant and direct approach for conversion of nitriles
into amidines and is shown in Scheme 3
(Boere et al. 1987). This approach was utilized in
the preparation of the highly active naphthalene-
biphenyl diamidine presented in Scheme 3 (Chackal-
Catoen et al. 2006) and has been extensively used in
other systems (Hu et al. 2008, 2009; Farahat et al.
2010, 2011; Branowska et al. 2010; Ismail et al. 2011).
This process involves the nucleophilic addition of a
silyl protected amide anion to the nitrile group. The
reaction is worked up with HCl/EtOH which both
de-protects the nitrogen atom and forms the hydro-
chloride salt of the amidine. This approach is limited
Fig. 3. Representative examples of diamidines, amidoximes, methamidoximes with some known pharmacokinetic
properties.
Fig. 4. Representative examples of AIAs tested against intracellular Leishmania. Panel A – Compounds possessing
potent antileishmanial activity (IC50 values <1 μM). Panel B – Compounds that are inactive (IC50 values >10 μM).
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to preparation of unsubstituted amidines. If acidic
hydrogen is present in a molecule that on de-
protonation yields an anion that is in conjugation
with the nitrile group, deactivation of the system to
nucleophilic attack occurs, thus formation of the
amidine often fails.
Bis-arylimidamides are readily prepared from bis-
nitro analogues as illustrated in Scheme 4 (Stephens
et al. 2001; Wang et al. 2010). The iso-propoxy
compound DB766 (Fig. 1) and its analogues were
proved to be highly effective in animal models for
intracellular obligatory parasites (Wang et al. 2010;
Batista et al. 2010a,b; Da Silva et al. 2011a,b, 2012)
The bis-nitro compounds can be reduced to the
corresponding bis-amino analogues by either of
two standard methods; catalytic hydrogenation or
stannous chloride reduction. The target AIAs are
readily obtained by reaction of the bis-amine with
S-(2-naphthylmethyl)pyridine-2-carbimidothioate.
The major limitation of this method is that a
relatively basic amine is required as a substrate since
bis-amines containing strong electron withdrawing
groups fail to react (Stephens et al. 2001). Other
synthetic approaches to these type AIAs have been
reported (Hu and Boykin, 2009). Both classical
diamidines and bis-arylimidamides are attractive
candidates for use against various parasitic diseases;
however for one to become useful it is essential that
it is economical to synthesize. The synthesis of either
class by one or more of the methods outlined in
Schemes 1–4 are likely to be at a reasonable cost. The
cost of synthesis for the required bis-nitrile or bis-
nitro precursor, however, can be quite variable and
consideration should be given to linker selection early
in the drug development process.
MECHANISMS OF ANTIPARASITIC ACTION
In spite of many years of study by a number of
laboratories, it has proven surprisingly difficult to
definitively establish a single mechanism of anti-
parasitic action of dications, and various targets have
Fig. 5. Representative examples of amidines tested against Trypanosoma cruzi in in vitro and in vivo studies.
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been suggested including both mitochondrial and
nuclear DNA, microtubules, acidocalcisomes, and a
range of enzymes (Tidwell and Boykin, 2003; Arafa
et al. 2005; Soeiro et al. 2005; Wilson et al. 2005,
2008; Werbovetz, 2006; Batista et al. 2010a,b; Paine
et al. 2010;Ward et al. 2010). These compounds have
typically been shown to selectively target AT-rich
DNA and to form a complex in the minor groove
of the double helix. This observation has led to
considerable research to determine whether DNA is
at least one of their cellular targets. Even for these
fairly simple but structurally diverse compounds,
however, it now seems certain that there is more than
1 bioreceptor in parasitic microorganisms. Both the
mitochondrial and nuclearDNAs arewell established
as dication targets and the strongest evidence
indicates that DNA functional destruction is related
to their antiparasitic action (Wang and Englund,
2001; Soeiro et al. 2005, 2008; Wilson et al. 2005,
2008; Werbovetz, 2006; Soeiro and De Castro,
2009; Chowdhury et al. 2010). In trypanosomes,
Leishmania and related organisms, the mitochondrial
kinetoplastDNA (kDNA) network typically contains
DNA minicircles that encode for guide RNAs
that edit transcripts from the maxicircle DNA,
which corresponds to the mitochondrial genome
(Shapiro and Englund, 1995). The thousands of
DNA minicircles are topologically linked in a planar
disc array (Shapiro and Englund, 1995; Klingbeil
et al. 2001), exhibiting, as does the genomic DNA
of Plasmodium, greater AT content (>75%), with
extensive, closely spaced, sequences that act as strong
binding sites and selective therapeutic target sites for
these dicationic compounds (Carlton, 2003; Purfield
et al. 2009).
The heterocyclic dications typically have absorp-
tion bands near 350–400 nm and emission bands in
solution in the blue region near 450 nm (Wilson et al.
1990). By fluorescence (Fig. 2) and transmission
electron microscopy analysis (Fig. 6), it is possible to
follow the compound distribution and evaluate their
ultrastructural effect on the treated parasites (Stewart
et al. 2005; Lanteri et al. 2006; Werbovetz, 2006;
Hu et al. 2008; Batista et al. 2010a,b). Results for a
number of dications showed that they are first
preferentially located in the kinetoplast and seconda-
rily in the nucleus of Trypanosoma brucei, T. cruzi
and Leishmania (Wang and Englund, 2001; Lanteri
et al. 2006; Mathis et al. 2006, 2007; Batista et al.
2010a, 2010b; Chowdhury et al. 2010). The kDNA
and kinetoplast itself are extensively modified shortly
after treatment and the latter structure is generally
destroyed about 24 h after diamidine exposure,
leading to parasite death. In an important study, the
Barrett group demonstrated that pentamidine targets
the kinetoplast in Leishmania mexicana and that its
concentration in the nucleus, cytoplasm and other
cell compartments is very low (Basselin et al. 2002).
In a strain of pentamidine-resistant L. mexicana
Fig. 6. Transmission electron microscopy of Neospora
caninum tachyzoites cultured in the absence (A, B) and
presence (C–E) of the arylimidamide DB745. (A) and (B)
show control cultures at 48 h post-infection. Tachyzoites
are situated within the cytoplasm and proliferate within a
parasitophorous vacuole, surrounded by a
parasitophorous vacuole membrane (arrows in (B)).
Rhoptries (rop), micronemes (mic), dense granules (dg),
mitochondria (mito) and the nucleus (nuc) are visible.
Arrows in (A) pointed to the conoid at the apical end of
the parasites, while arrows in (B) indicate the
parasitophorous vacuole membrane. The nuclei (nuc)
contain electron-dense chromatin, and white arrows point
to the intact nuclear membrane. Hcmito=host cell
mitochondria, hcnuc=host cell nucleus,
pvtn=parasitophorous vacuole tubular network forming
the matrix of the vacuole. Bar in (A)=0·84 μm; bar in
(B)=0·55 μm. (C–E) represent images of tachyzoites after
treatment with 1 μM DB745 for 24 h (C) and 48 h (D–E).
In (C), separated nuclear membranes are pointed out with
white arrows. Cytoplasmic vacuoles (v) are partially filled
with membranous and/or electron-dense material of
unknown origin. Bar=0·65 μm. (D) Tachyzoites after
48 h of culture but still fused together, showing increased
vacuolization (v) and large numbers of dense granules
(dg). (E) Higher magnification view of the fused contact
sites shown in (D). Parasites are clearly separated by two
distinct inner membranes, but held together by the outer
plasma membrane. The black arrow indicates the blind
ending of the inner membrane of the upper tachyzoite,
the white arrow shows the contact site with the outer
membrane fusing the parasites together. Bars in
(D)=0·4 μm; (E)=0·25 μm.
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Scheme 1. Synthesis of furamidine by the Pinner method.
Scheme 2. Synthesis of an aromatic diamidine via a diamidoxime.
Scheme 3. Synthesis of an aromatic diamidine using LiN(TMS)2.
Scheme 4. Synthesis of the arylimidamide DB766.
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organisms, this amidine (Fig. 1) passed the plasma
membrane as usual, but did not efficiently achieve
access to the mitochondrion, thus not being able to
destroy the kDNA. As no other significant biological
target was detected in those parasites, these data
indicated that the antiparasitic activity of amidines,
like pentamidine requires their uptake and delivery to
the mitochondrion, allowing binding to the kDNA.
As described above, considerable current literature
data support kDNA as a primary antitrypanosomal
biological target of these dications and there is also
new evidence for their mechanism of action in
T. brucei. Results from Englund´s laboratory showed
that blockage of kinetoplast replication through RNA
interference of topoisomerase II production led to the
death of bloodstream parasites (Wang and Englund,
2001). These findings clearly demonstrate that the
kinetoplast is essential for these parasite forms. More
recent research from the same group has definitively
shown that in T. brucei compounds that act as kDNA
binders destroy the kinetoplast structure and cause
parasite death (Chowdhury et al. 2010). The same
group reported in T. brucei that death triggered by
ethidium bromide (EB – an intercalating agent also
used as a fluorescent marker for DNA) was linked to
its effect on parasite kDNA (Chowdhury et al. 2010).
However, the existence of viable parasites lacking
kDNA (dyskinetoplastic) has been a source of a long-
lasting controversy about the role of the kinetoplast as
target and whether kDNA loss could be in fact the
mechanism of killing. Additional studies indicated
that kDNA is essential in bloodstream forms of
T. brucei and that dyskinetoplastic parasites only
survive due to a compensating mutation in the
nuclear genome (Schnaufer et al. 2005; Lai et al.
2008). These important observations led the Englund
group to re-study the question of kDNA as a drug
target. They found that binding of EB to covalently
closed kDNA minicircles released from the network
during replication caused extensive DNA super-
twisting, helix distortion, inhibition of replication,
and resulted in kDNA loss, culminating in parasite
death. Interestingly, although EB could also kill
dyskinetoplastic trypanosomes by targeting nuclear
DNA, death occurred at higher concentrations
through inhibition of nuclear DNA replication.
The effect on kDNA occurred at around a 10-fold
lower drug concentration as compared with the effect
on the nuclear DNA, indicating the kinetoplast as
the primary target but that the effect on nuclear
replication can also contribute to cell killing
(Chowdhury et al. 2010). While the studies per-
formed by Englund’s laboratory were performed
with EB, these data may contribute to the knowledge
regarding the mechanism of action of other com-
pounds that act in the kinetoplast structure. Evidence
obtained by transmission electron microscopy
showed that some aromatic dications also target
the mitochondrial kinetoplast in Leishmania
(Hu et al. 2008) and T. cruzi (De Souza et al. 2006),
demonstrating that kDNA targeting of these com-
pounds holds for, at least, pathogenic kinetoplastids.
Clearly, additional studies are needed to provide
definitive proof regarding the mechanism of action of
these dicationic compounds on different organisms.
It should be noted that binding to DNA may be
only the initial step in the biological activity of most
of these dications and other mechanisms are yet to
be defined. It is likely that the functions of DNA-
targeted control proteins or enzymes are directly or
indirectly modified by dication binding to DNA for
antiparasitic activity to occur. For this reason some
optimum level of DNA binding is required, but a
direct correlation of DNA binding constants and
biological activity is not generally observed
(Daliry et al. 2011). The experimental results
obtained so far in trypanosomes and Leishmania led
to a general concept that diamidines act on these
parasites by targeting their kinetoplast (Hu et al.
2008; Wilson et al. 2008). The destruction of the
kinetoplast by diamidines could occur, for example,
by compound interference with topoisomerase II-
catalysed opening and rejoining of kDNA mini-
circles. In agreement with this model, Shapiro and
Englund (1990) showed in a fundamental set of
experiments that pentamidine, berenil and other
antitrypanosomal drugs bind to DNA and selectively
target kinetoplast topoisomerase II leading to its
linearization. There are other DNA replication steps
in the large, catenated kDNA network where drug
binding could also cause replication errors and DNA
degradation (Chowdhury et al. 2010). Additionally,
the antiparasitic activity and relatively low host
toxicity of dications suggest that the intricate
structure of the catenated kDNA network must be
also considered. Since there are thousands of DNA
minicircles in the network, each with multiple closely
spaced AT sequences, a very small compound-
induced error percentage in the normal biological
functions of the kinetoplast could be enough to cause
destruction of the network, kinetoplast disintegration
and cell death. This structure is unique to kineto-
plastid organisms and this fact may account for their
generally low cytoxicity to mammalian cells. Minor
topological effects of the compounds at the repeated
AT sequences of the kDNA network could act in
synergy, leading to a biologically catastrophic effect
in the treated parasites.
It seems likely that mitochondrial functions
in African trypanosomes are much more complex
than previously realized. RNA editing, for example, a
key kinetoplast function, has been demonstrated to
be essential for survival of bloodstream forms of
T. brucei (Schnaufer et al. 2001). Given the normal
close coupling of kDNA, nuclear DNA and cell
division; it is also possible that the loss of the
kinetoplast disrupts normal cell division (Schnaufer
et al. 2002). An interesting additional aspect of the
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alterations induced by diamidines on the kinetoplast
topology and physiology is the occurrence of para-
sites expressing programmed cell death character-
istics (Schnaufer et al. 2002; De Souza et al. 2006).
Clearly, the kinetoplast is essential for trypanosomes
and its destruction by diamidine treatment can yield
the observed biological activity. In summary, 3 clear
statements can be made with regard to the antipar-
asitic mechanisms of dicationic amidines. The kDNA
(in kinetoplastid organisms) is a primary target of
these dications which generally cause destruction
of the kinetoplast. Nuclear DNA is a secondary target
in these organisms while it is at least one of the
main targets in other parasites such as Plasmodium
(Purfield et al. 2009), although the evidence for this
mode of action is less definitive. The nuclear
mechanism is dominant in dyskinetoplastic organ-
isms and this secondary mechanism accounts for the
long held, but completely incorrect, view among
some scientists that the kinetoplast could not be
the primary target of any antiparasitic drug. Third,
there are certainly other mechanisms of action of
some compounds in this large and diverse group of
molecules, but the evidence for any other specific
mechanism is very limited and certainly not defini-
tively established at present. An obvious corollary
to these statements is that much more research
on the antiparasitic mechanisms of this important
set of compounds is urgently needed.
PHARMACOKINETICS
Absorption
As briefly presented above, the classical antiparasitic
diamidines, e.g. pentamidine and furamidine
(Fig. 1), are not well-absorbed through the gastro-
intestinal (GI) tract after oral administration, and
hence are given by injection to achieve the desired
bioavailability. The in vitro permeability of furami-
dine measured in Caco-2 cell monolayers was low,
similar to that of the paracellular permeabilitymarker
mannitol, and it was modulated by the absence of
Ca2+, suggesting a paracellular route for traversing
epithelial membranes (Zhou et al. 2002). As stated in
the section ‘Design and synthesis’, the high pKa
values and the resulting positive charge at physio-
logical pH preclude diamidine molecules from
passively diffusing across lipid membranes, thus
carrier-mediated transport is required to achieve
cellular uptake. To overcome the absorption limit-
ation of cationic diamidines, pro-drug strategies and
novel structural designs have been employed to
enhance oral absorption. The acid dissociation
constant of the amidine group can be modulated
by N-derivatization to form the amidoxime (e.g.
DB290, DB821 and DB840) and alkyloxy prodrugs
(e.g. pafuramidine, DB844 andDB868) (Fig. 3). The
measured pKa values for DB290 and pafuramidine
were 5·2 and 4·1, respectively, significantly lower
than that of furamidine (pKa=11·8). This lowered
pKa resulted in an 85-fold increase of the per-
meability of pafuramidine relative to furamidine
(Zhou et al. 2002) although no increase was detected
for DB290 due to extensive metabolism within the
cells (Saulter, 2005). In addition to the pro-drug
approach, amidine groups were modified to form
AIAs by attaching the imino group of the amidine to
an anilino nitrogen (e.g. DB745 and DB766; Figs 1
and 4). This modification lowered the pKa to 7·1 and
7·4 for DB745 and DB766, respectively, and con-
tributed to their oral activity against Leishmania and
T. cruzi in mice and hamsters (Wang et al. 2010,
Batista et al. 2010a,b; Zhu et al. 2012).
Distribution
Once absorbed, the cationic amidines as well as AIAs
exhibit extensive distribution into various tissues.
After a single oral dose (10 mg kg−1) of radio-isotope
labelled pafuramidine to rats, concentrations of
radioactivity in nearly all tissues exceeded those in
blood (Midgley et al. 2007).Liverwas themajor organ
of drug accumulation, where 13–21% of radioactivity
was found 7 days post-dose and essentially all was in
the form of the active compound furamidine. Other
tissues, with significant concentrations of radioac-
tivity included: kidney, adrenal, nasal mucosa,
intestine and pancreas. Concentrations of radioac-
tivity in the brain were similar to those in plasma,
whereas they were below the limit of detection in the
cerebrospinal fluid. The limited CNS exposure is
consistent with the lack of cures for pafuramidine in
the mouse and monkey models of second-stage HAT
(Mdachi et al. 2009; Wenzler et al. 2009). More
recently, novel aza-analogues of furamidine (DB820
and DB829, Fig. 3) and their methoxy pro-drugs
(DB844 and DB868) (Fig. 3) have cured animals
in the second-stage mouse (100%) and monkey
(43–100%) models of HAT (Wenzler et al. 2009;
Thuita et al. 2012; J. K. Thuita and R. Brun, personal
communication), suggesting an improved brain pen-
etration by the new aza-analogues. The AIA DB766
accumulated preferentially to the antileishmanial
target organs (i.e. liver and spleen), as well as kidneys,
with maximum concentrations up to 26-fold higher
than those in plasma (Wang et al. 2010). The com-
pound did not appear to get into the brain efficiently
relative to the above tissues, with concentrations
generally close to or below the corresponding plasma
concentrations. Studies to delineate the mechanisms
of the differential brain distribution of cationic
diamidines arewarranted and are currently underway.
Metabolism
Berger and coworkers demonstrated that pentami-
dine was extensively metabolized in the perfused rat
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livers with only 15% of recovered radioactivity as
pentamidine after 4 h incubation (Berger et al. 1992).
Two major metabolites were the alkyl linker oxi-
dation products, accounting for approximately 62%
of recovered radioactivity. Amidoxime formation
through N-hydroxylation of pentamidine was a
minor reaction pathway, accounting for <1% of the
recovered radioactivity. Unlike pentamidine, little
metabolism has been observed for diamidines with a
furan linker (e.g. furamidine, DB820 and DB829,
Figs 1 and 3) replacing the alkyl chain in the
pentamidine. As discussed in the section ‘Design
and synthesis’, various pro-drugs of diamidines have
been designed to improve oral bioavailability, by
masking the positive charge of the amidine moiety
using hydroxy, alkyloxy, acetoxy and amino acids
(Clement and Raether, 1985; Boykin et al. 1996;
Ismail et al. 2003; Kotthaus et al. 2011). Bio-
transformation of pafuramidine (Fig. 3), themethoxy
pro-drug of furamidine, to the active furamidine
is complex, involving multiple steps of sequential
oxidative O-demethylation and reductive
N-dehydroxylation reactions that are catalysed
by cytochrome P450 enzymes and the cytochrome
b5/NADH b5 reductase system, respectively
(Saulter et al. 2005; Wang et al. 2006, 2007). Similar
enzymatic reactions have been shown to be involved
in the biotransformation of aza-analogues of pafur-
amidine (DB844 and DB868) to their respective
active diamidines (DB820 and DB829) (Ansede et al.
2005; Generaux et al. 2013). Metabolism studies on
AIAs are limited due to their early stage in drug
development. Previous metabolic stability results
using liver microsomes indicate that mice and
hamsters metabolize AIAs more extensively than
rats and humans (Wang et al. 2010). However, no
information is available on the metabolite identity.
Excretion
Following oral administration in rats, pafuramidine
was excreted predominantly in the feces (approxi-
mately 62% of dose) as the original pro-drug (20% of
dose), furamidine (22% of dose) and an intermediate
mono-amidine metabolite (10% of dose) (Midgley
et al. 2007). Urinary excretion accounted for less than
5% of dose. A considerable portion of the dose
(6–21%) was retained in the body (mainly in the liver
as furamidine) at 7 days post-dose and was slowly
eliminated. Biliary excretion accounted for 14–26% of
dose in the first 48 h post-dose. In general, methoxy
pro-drugs of diamidines are eliminated rapidly
(plasma t1/2 ranging from 1 to 18 h in rats and
monkeys), whereas the active diamidines exhibit
extensive peripheral distribution (plasma t1/2 ranging
from days to weeks) and are often detectable in
accumulating tissues (e.g. liver) several months post-
dose (Donnelly et al. 1988; Midgley et al. 2007;
Thuita et al. 2012). Experimental excretion data for
other diamidines/prodrugs and AIAs are scarce, but
presumably follow a similar pattern.
As reviewed above, the most successes in improv-
ing dicationic amidines against trypanosomiasis
infection like HAT are those that optimize pharma-
cokinetic properties in terms of oral bioavailability
and/or target-tissue penetration, as pentamidine
remains among the most active trypanocidal diami-
dines against HAT. Greater membrane permeability
also contributed to the potent activity of AIAs against
intracellular Leishmania and T. cruzi parasites.
Future efforts should consider investigating mech-
anisms of tissue uptake of the diamidines to reduce
unwanted high tissue accumulation, especially in the
liver and kidney. The aza analogue DB829 represents
such a new diamidine, which accumulated less in the
rat liver and kidney (by approximately 2- and 5-fold,
respectively), and yet showed twice more systemic
exposure than furamidine following intravenous
administration (Paine et al. 2010). DB868 (Fig. 3),
the methoxy pro-drug of DB829, was also better
tolerated in vervet monkeys than its predecessors and
cured the monkeys in the acute and CNS model of
HAT after oral administration (J. K. Thuita and
R. Brun, personal communication).
EFFICACY AND SELECTIVITY OF AMIDINES AND
THEIR DERIVATIVES AGAINST LEISHMANIA
Leishmania parasites cause a spectrum of disease
ranging from cutaneous lesions to potentially fatal
visceral infections of the mononuclear phagocyte
system depending on the species of infecting organ-
ism. These parasites alternate between an elongated
promastigote form that develops in the sandfly vector
and a smaller, sessile amastigote form that exists
within the macrophages of an infected host. Recent
epidemiological studies estimate that between 0·7 and
1·2 million cases of cutaneous leishmaniasis occur
annually, while anywhere from 0·2 to 0·4 million
cases of visceral disease and between 20 000 and
40 000 deaths due to visceral leishmaniasis occur each
year (Alvar et al. 2012). Chemotherapy for leishma-
niasis has traditionally relied on the pentavalent
antimonial drugs sodium stibogluconate and meglu-
mine antimoniate; treatment for both visceral and
cutaneous disease still depends on these injectable
antimonials in most areas. However, resistance to
pentavalent antimonials on the Indian subcontinent,
a focal point for visceral leishmaniasis, has led to the
increased use of the parenteral drugs amphotericin
B and paromomycin as well as miltefosine, the first
oral drug for the treatment of this disease (Picado
et al. 2012). Unfortunately, all of these agents have
one or more weaknesses, including adverse effects,
high cost, the requirement of a long course of
treatment, and fears due to favourable conditions
for the development of drug-resistant parasites (Croft
and Olliaro, 2011). A safe, effective and inexpensive
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oral treatment would be a welcome addition for the
treatment of leishmaniasis, either as a component of
combination therapy in areas where drug resistance
has been reported or as a convenient form of
monotherapy in regions where resistance has not
been documented. Pentamidine (Fig. 1) was used in
the past for the treatment of antimony-resistant
visceral leishmaniasis infections, but response rates
have decreased with time (Olliaro et al. 2005) as
illustrated by a clinical study published in 2009
showing that pentamidine was inferior to ampho-
tericin B in treating antimony-resistant visceral
leishmaniasis in Bihar, India (Das et al. 2009).
Pentamidine is currently the treatment of choice for
cutaneous leishmaniasis caused by Leishmania guya-
nensis (van der Meide et al. 2009; Hu et al. 2012) and
is also a recommended drug against Leishmania
panamensis (World Health Organization, 2010) de-
spite the fact that the clinical antileishmanial efficacy
of pentamidine is relatively low. For example, while
the administration of three 4mg kg−1 doses of
pentamidine by the intramuscular route was as
effective as higher doses of meglumine antimoniate
against cutaneous leishmaniasis caused by L. guya-
nensis, the cure rate after 6 months was only 58·1%
(Neves et al. 2011).
Pentamidine possesses good in vitro activity
against extracellular Leishmania, but does not com-
pletely clear Leishmania-infected macrophages at
concentrations that are not toxic to the host cell
(Berman and Wyler, 1980; Gebre-Hiwot et al. 1992;
X. Zhu, unpublished observations). Many other
diamidine-containing molecules also possess in vitro
activity against Leishmania (Mayence et al. 2004;
Huang et al. 2006; Bakunova et al. 2007, 2009,
Bakunov et al. 2010), but the potency of these agents
against intracellular Leishmania and their efficacy in
animal models of leishmaniasis was not reported.
Earlier papers indicated that diamidines possess
limited activity in animal models of leishmaniasis
(Hanson et al. 1977; Steck et al. 1981; Macharia et al.
2004), an observation that may also restrict the
clinical utility of pentamidine and other diamidines
for treating cutaneous and visceral leishmaniasis. The
low in vivo efficacy of diamidines may be a result of
the dicationic nature of these compounds precluding
oral bioavailability and also limiting the passive
diffusion of these molecules across membranes
(see details in the sections ‘Introduction’ and
‘Mechanisms of antiparasitic action’). This may be
a major problem in the treatment of intracellular
parasites such asLeishmania, where a drug is required
to cross at least 3 sets of membranes (host cell
membrane, parasitophorous vacuole membrane,
parasite cell membrane) to enter the intracellular
organism.
In 2003, Stephens et al. showed that AIAs possess
potent activity against both extracellular and intra-
cellular Leishmania donovani, with the potency being
higher against intracellular organisms (Stephens et al.
2003). With their lower pKa values (*7) and greater
lipophilicity compared with pentamidine (Wang
et al. 2010), AIAs may exhibit superior activity
against intracellular Leishmania due to improved
membrane permeability. Several different structural
variants of bis-AIAs (compounds containing 2
terminal amidine groups attached to a heterocycle)
have now been prepared. The initial paper reporting
the potent activity of AIAs against intracellular
Leishmania described the synthesis and evaluation
of a series of 8 symmetrical bis-AIAs containing
different functional groups on the phenyl rings of the
diphenylfuran linker. The potency of these com-
pounds against intracellular L. donovani ranged from
150–3600 nM (Stephens et al. 2003). A broader series
of over 50 symmetrical bis-AIAs was reported by
Collar et al. in 2011; these compounds were tested for
their ability to reduce intracellular Leishmania
amazonensis parasite burdens. Compounds with
2-pyridyl terminal groups and fairly large hydro-
phobic substitutions on the diphenylfuran linker
showed potent activity. However, when the substi-
tutions became too large (i.e. benzyloxy or iso-
butoxy), potency was diminished. In terms of the
terminal groups, the 2-pyridyl terminal substitution
was superior to other heterocyclic substitutions
such as 2-pyrimidyl, 2-pyrazinyl and 2-pyrrolyl,
although a compound with a 2-methyl-5-thiazolyl
terminal group retained potent intracellular activity
(Collar et al. 2011). Symmetrical bis-AIAs con-
taining different linker groups have also been
synthesized and evaluated against intracellular
Leishmania. Compounds with 1,4-phenyl and
1,4-phenylenediamine linkers showed dramatically
reduced antileishmanial potency, while compounds
with 4,4′-biphenyl, 4,4′-oxydianiline and 4,4′-oxybis
(methylene)dianiline linkers retained antiparasitic
activity (Banerjee et al. 2012). Bis-AIAs containing
unsymmetrical substitutions on the diphenylfuran
linker also retain potent activity against intracellular
Leishmania; an AIA bearing an isopropoxy substi-
tution on one of the 2 phenyl rings of the
diphenylfuran linker displayed an IC50 value of
5·3 nM against L. donovani and 93 nM against
L. amazonensis (Reid et al. 2012). A structure-activity
map summarizing the in vitro antileishmanial po-
tency of bis-AIAs was recently published (Reid et al.
2012) and examples of active and inactive bis-AIAs
against intracellular Leishmania are given in Fig. 4.
The most promising AIAs in terms of their in vivo
antileishmanial potential are 2,5-bis[2-(2-propoxy)-
4-(2-pyridylimino)aminophenyl]furan and the
closely related 2,5-bis[2-(2-cyclopentyloxy)-4-(2-
pyridylimino)aminophenyl]furan. When prepared
as its dihydrochloride salt form, the 2-propoxy
compound is known as DB766, while as its dimesy-
late, it is termed DB1960. The cyclopentyloxy
compound dihydrochloride salt has the code name
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DB1852, while the corresponding dimesylate is
DB1955 (Figs 1 and 4). DB766 displayed IC50 values
of 36, 87 and 14 nM against intracellular L. donovani,
L. amazonensis and Leishmania major amastigotes,
respectively, comparable to the in vitro potency of the
clinically applied antileishmanial drug amphotericin
B. When tested orally in animal models of visceral
leishmaniasis, DB766 reduced L. donovani parasite
burdens in the liver by 71% and 89% when
administered to infected BALB/c mice and golden
hamsters at 100mg kg−1 day−1×5; the compound
was not mutagenic in the Ames test (Wang et al.
2010). DB1852 was less active than DB766 against
intracellular Leishmania in vitro, but showed in vivo
potency similar to that of DB766 in the murine
visceral leishmaniasis model. The corresponding
mesylate salts of DB766 and DB1852, DB1960 and
DB1955, respectively, were 5·3-fold and 3·1-fold
more soluble than their hydrochloride salt counter-
parts, allowing for repeat-dose toxicology studies to
be performed at doses up to 500mg kg−1 day−1. The
maximum tolerated dose of both mesylate salts was
found to be <100mg kg−1 day−1 by the oral route,
with liver, kidney and haematological toxicity ob-
served at high doses and microscopic findings in the
GI tract observed at lower doses. DB1960 was more
toxic than DB1955, but neither compound exhibited
a sufficient therapeutic window to move forward
with pre-clinical development (Zhu et al. 2012).
Unfortunately, other bis-AIAs that display potent
in vitro antileishmanial activity are more toxic than
DB766, DB1955 and DB1960 in vivo (Banerjee et al.
2012; Reid et al. 2012 and X. Zhu, unpublished
observations). Bis-AIAs are extremely potent against
intracellular L. donovani (IC50 values in the mid to
low nanomolar range), but toxicity issues have
precluded the further development of the class as
candidates against visceral leishmaniasis. Since the
mechanism of action of the AIAs is unknown, better
understanding of the target(s) of the AIAs could lead
to the design of more selective agents with a greater
therapeutic window.While diamidines cause dilation
of the Leishmania mitochondrion (Croft and Brazil,
1982; Hu et al. 2008), ultrastructural investigation of
the effects of DB766 in L. donovani axenic amasti-
gotes reveals little effect on this parasite organelle
(T. Pandharkar, unpublished observations). The re-
sults of further mechanistic investigations with AIAs
will hopefully benefit future antileishmanial drug
discovery efforts.
EFFICACY AND SELECTIVITY OF AMIDINES AND
THEIR DERIVATIVES AGAINST T. CRUZI
The obligatory intracellular protozoan, T. cruzi is
the aetiological agent of Chagas disease, an important
and neglected tropical disease, which affects
more than 10 million people in endemic areas of
Latin America (Dias, 2009). Chagas disease has
2 phases: the acute, which appears shortly after the
infection, and the chronic phase that develops in
about 20–30% of the infected individuals, after a
silent period of years or decades, called the indeter-
minate phase (Rocha et al. 2007). In both clinical
stages, tissue damage is directly induced by the
parasite, or indirectly, by parasite-driven immune
modulation (Coura and Borges-Pereira, 2012). The
main clinical manifestations of Chagas disease are
cardiac and/or digestive alterations but the mechan-
isms that govern this pathogenesis are not fully
understood (Marin-Neto and Rassi, 2009). Due to
the well-known undesirable side effects, and the
occurrence of parasite strains naturally resistant to
both nitro-heterocyclic compounds (Benznidazole
and Nifurtimox) associated with their poor efficacy
in the later chronic disease stage, the identification of
novel anti-T. cruzi agents are justified (Romanha
et al. 2010). However, as a consequence of the
low interest of most pharmaceutical companies
and the lack of standardized/proper experimental
protocols and animal models for drug screening,
very few compounds moved to clinical trials, includ-
ing 2 triazole inhibitors of the parasite’s C14α
sterol demethylase: posaconazole (Schering-Plough
Research Institute) and a pro-drug of ravuconazole
(E1224 (Eisai Company)) (De Castro et al. 2011).
However, these azoles have important limitations
mainly related to their high costs and the potential to
induce parasite resistance as they enhance T. cruzi
sterol 14alpha-demethylase gene expression and
require increasing doses to maintain constant cellular
growth inhibition (Lepesheva and Waterman, 2011).
Thus, the identification of other promising trypano-
cidal candidates is urgently needed. In recent
years, a considerable amount of data has been
collected regarding the effect of amidine-containing
molecules against T. cruzi (Soeiro and De Castro,
2011). While pentamidine does not display potent
activity (>32 μM) on bloodstream trypomastigotes of
T. cruzi (Zhu et al. 2012), other aromatic diamidines
show considerable in vitro effects (DeSouza et al. 2004,
Pacheco et al. 2009; Batista et al. 2010a; Daliry et al.
2011; Da Silva et al. 2011a). For instance, 3-bromo-
4-methyl-2,5-bis(4-amidinophenyl)thiophene
(DB1362 – see Fig. 5) induced a dose-dependent
trypanocidal activity giving an IC50 value of 6 μM,
and provided a partial reduction of the parasitaemia
levels in an experimental mouse model of acute
infection using the Y strain ofT. cruzi (Da Silva et al.
2008). DB569, anN-phenyl derivative of furamidine
(DB75), exhibited a dose- and time-dependent
activity towards both bloodstream (IC50=2 μM) and
amastigotes (>4 μM) of different T. cruzi strains
(De Souza et al. 2004). In vivo, DB569 significantly
reduced the cardiac parasite burden in mice, partially
increased survival rates, and lowered the levels of
alanine aminotransferase and creatinine, indicating a
protective role against renal and hepatic lesions
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induced by infection (De Souza et al. 2007). DB569
also protected infected mice from electric cardiac
alterations due to T. cruzi invasion possibly due to
the reduced parasitism associated with the modu-
lation of an aggressive host immune response, since
this amidine (but not benznidazole) decreased CD8+
T cells levels at the inflamed hearts of the infected and
treated mice (De Souza et al. 2007). Interestingly,
diamidines like DB569 control intracellular parasit-
ism more efficiently when professional phagocyte
cells such as macrophages are used as host cells as
compared with non-professional phagocytes such as
cardiac cells (De Souza et al. 2004). These results
suggest that depending on the host cell type, different
levels of trypanocidal events may be triggered
directly by these aromatic compounds in mammalian
cells, contributing to the control of parasite prolifer-
ation. In fact, E. M. De Souza and M. N. C. Soeiro
(unpublished data) demonstrate the ability of amidines
like DB569 to induce nitric oxide production by
mammalian cells giving strong support that not only
the antiparasitic mechanism of action of these
compounds should be more thoroughly investigated
but also, most importantly, their potential effect on
host cells metabolism and activation of trypanocidal
responses that could also limit the parasite burden.
As described for Leishmania, AIAs (especially bis-
AIAs – see the section ‘Efficacy and selectivity of
amidines and their derivatives against Leishmania’)
are highly potent againstT. cruzi, with many of them
displaying superior efficacy as compared with classi-
cal aromatic diamidines (e.g. DB75 and pentamidine)
(De Souza et al. 2004; Da Silva et al. 2007; Pacheco
et al. 2009). Studies with bloodstream forms demon-
strated that the AIA DB766 (IC50=60 nM, Batista
et al. 2010a) is about 260-fold more potent than
DB75 (IC50=16 000 nM, De Souza et al. 2007),
showing that minor modifications of the chemical
structure of amidine-containing molecules can result
in higher selectivity and efficacy. As also discussed for
Leishmania in the section ‘Efficacy and selectivity of
amidines and their derivatives against Leishmania’ of
the present review, the superior activity of AIAs
comparedwith amidine compoundsmay be related to
their lower pKa values and greater lipophilic char-
acter, contributing to their efficient entrance into host
and parasite cell membranes. In fact, despite the fact
that T. cruzi disrupts the parasitophorous vacuole
membrane and proliferates freely within the cyto-
plasm of the host cells, in order to be active against
this protozoan infection, especially during the late
chronic phase, a desirable drug candidate must cross
both T. cruzi and host plasmalemmas to reach the
parasite intracellular milieu and act on its cellular
targets. DB766 exhibited strong activity (in the
nanomolar range) and excellent selectivity on intra-
cellular amastigotes, showing striking effects upon a
large panel of T. cruzi strains including parasite
isolates that circulate in peridomiciliar and sylvatic
ecotopes from different regions from Brazil (Ceará
State and Amazon region), and those that are
naturally resistant to benznidazole and nifurtimox
(e.g. Colombiana and YuYu), with higher efficacy
in vitro than the reference drugs (Batista et al. 2010a).
DB766 as well as several other AIAs (such as DB745,
DB1831 and DB1868 – Figs 4 and 5) keep a high
activity at 4 °C in the presence of 96% mouse blood,
being at least 30·6-fold more effective than gentian
violet, the reference drug for blood therapy in Chagas
disease (Batista et al. 2010a, 2011; Da Silva et al.
2012). These results demonstrate the potential
application of AIAs in the prophylaxis of T. cruzi
infection acquired through contaminated blood
stored in blood banks. On the other hand, other
AIAs (like DB1852 – Fig. 5) showed decreased
activity when incubated at 4 °C even in the absence of
blood, suggesting that such a decrease may be related
to impairment of drug uptake due to a transport-
mediated mechanism and/or to decreased cellular
target metabolism (Da Silva et al. 2011a, b).
Due to the high efficacy and selectivity of novel bis-
AIAs, some compounds such as DB766 (selectivity
index (SI) >533) were assessed with in vivo models
(Batista et al. 2010a). DB766 suppressed the parasite
load in the blood and cardiac tissues (80–>99%
reduction), presented similar efficacy as benznidazole
in mouse models of T. cruzi-infection employing Y
(moderated resistant) and Colombiana (high resist-
ant) strains, using oral and intraperitoneal (i.p.) doses
up to 100mg kg−1 day−1 (given after the establish-
ment of parasite infection), and provided 90–100%
protection against mortality (Batista et al. 2010a).
The effectiveness of this AIA in eradicating intra-
cellular parasites (as we observed in cardiac cells
during in vitro and in vivo infection, Batista et al.
2010a) may be related to its pharmacokinetic
properties (see section on ‘Pharmacokinetics’) in-
cluding long half-lives and large volumes of distri-
bution (Wang et al. 2010). This issue is highly
relevant, since the poor activity of benznidazole
during the chronic stages of CD has been attributed,
at least in part, to its poor pharmacokinetic proper-
ties, such a relatively short half-life and limited tissue
penetration (Soeiro and De Castro, 2009). Although
it is not a pro-drug, DB766 showed good activity
upon oral administration (dose 100mg kg−1 day−1)
(Batista et al. 2010a). However, using a similar mouse
model of acute T. cruzi infection (Y strain), the
mesylate salt of DB766 (DB1960) only decreased the
parasitaemia levels by 46% when given orally at
100mg kg−1 day−1×5 (Zhu et al. 2012). It is possible
that the increased solubility of DB1960 may result
in decreased permeability and therefore lesser drug
accumulation in parasitized organs, resulting in lower
efficacy (Zhu et al. 2012).
Another highly effective AIA that has been
screened against T. cruzi and showed high activity
is DB1852, exhibiting IC50 values of 60 nM against
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bloodstream trypomastigotes (Y strain) (Da Silva
et al. 2011b). When assayed in vivo, the mesylate salt
of DB1852 (DB1955) had no effect on parasitaemia
when administered using the same dosing regimen as
DB1960 and DB766 in a similar mouse model of
acute infection (Y strain). The lower in vivo efficacy of
DB1960 and DB1955 may be due to their lower
accumulation in the heart and plasma of infected
mice, which are important sites of T. cruzi infection
(Zhu et al. 2012). Additionally, another point of
discussion is the fact that DB766, DB1955 and
DB1852 displayed similar effects upon bloodstream
forms (60–70 nM), but the former AIA was much
more potent against intracellular forms (IC50=25,
180 and 538 nM for DB 766, DB 1955 and DB1852,
respectively). Although a direct correlation between
in vitro and in vivo is not always found, cumulative
data suggest that the activity against intracellular
amastigotes, which are the reproductive forms in the
vertebrate host, represents a more reliable determi-
nant in the selection of effective compounds to move
from in vitro to in vivo assays (De Castro et al. 2011).
The excellent activity of DB766motivated the design
and synthesis of novel structurally related com-
pounds like the AIA – DB1831 (hydrochloride salt)
and its mesylate salt form (DB1965) (Da Silva et al.
2012). DB1831 displayed excellent activity against
bloodstream trypomastigotes (IC50=20 nM), and, as
did DB766, retained excellent efficacy at 4 °C (IC50
values of 80 and 24 nM with or without mouse blood,
respectively). When assessed against intracellular
amastigotes grown in cardiac cell cultures, DB1831
exhibited an outstanding IC50 of 5 nM already at 48 h
after the initiation of treatment, as well as very
high SI values (2900). Due to its poor solubility, a
methanesulfonic acid salt (DB1965) was obtained for
further in vivo analysis. DB1965 administered i.p. for
5 daily consecutive doses (starting at the onset of
parasitaemia) reduced parasitaemia levels by 93 and
99% when administered at doses of 12·5 and 25mg
kg−1, respectively, similar to the reference drug
(Da Silva et al. 2012). Although treatment with
12·5 mg kg−1 of DB1965 for 10 days suppressed
the parasitaemia and gave 90% protection against
mortality, longer periods of therapy were not
performed due to undesirable side effects (like
hyperactivity) and a combined treatment of 5mg kg−1
DB1965+50mg kg−1 benznidazole (suboptimal
dose) was chosen following the same protocol
previously carried out with DB766, under a scheme
of 20 daily consecutive doses (Batista et al. 2011).
However, despite the promising trypanocidal effects
of AIAs in combination with benznidazole, neither
DB766, DB1965 nor the reference drug induced
parasitological cure (Batista et al. 2011b; Da Silva
et al. 2012), possibly due to the highly stringent
protocol employed (male mice, only 20 days of
compound administration, starting treatment at the
onset of parasitaemia, using only positive infected
animals). In fact, previous studies performed in T.
cruzi-infected mouse models reporting high para-
sitological cure rates (e.g. benznidazole) employed
different protocols using female mice (instead of male
mice as used for AIAs), longer periods of treatment
(540 days) or abortive scheme (starting therapy 24 h
after parasite inoculation) (Urbina et al. 1998;Molina
et al. 2000; Bustamante et al. 2008). Although
displaying quite similar results as benznidazole,
DB1965 was not as active in vivo as DB766, especially
by p.o. administration and was also less well tolerated
according to acute toxicity studies (Da Silva et al.
2012). Since the only difference in structure between
DB766 and DB1831 concerns the terminal groups
(pyridine and pyrimidine, respectively), differences
in toxicity and efficacy between DB766 and DB1965
may also be attributed to this minor modification.
Thus, further investigations are required to sort out
this effect, allowing the design of novel AIAs bearing
pyrimidine and pyridine units since they seem to be
advantageous for retaining activity against T. cruzi.
When otherT. cruzi candidates that have moved (e.g.
ravuconazole with IC50=1 nM, Urbina et al. 2003) or
are expected to move soon to clinical trials (protease
inhibitors such as K11777 – McKerrow et al. 2009)
are compared with DB 766 (IC50=25 nM), similar
efficacy is found against intracellular amastigotes,
meriting further investigation on AIAs against
parasitic infection on intracellular microorganisms.
In fact, the biological activity of 7 novel AIAs was
recently assayed for 48 and 24 h against intracellular
parasites and bloodstream forms (Y strain), respect-
ively. The data demonstrated the outstanding trypa-
nocidal effect of AIAs against T. cruzi, especially
DB1853, DB1862, DB1867 and DB1868 (Fig. 6),
giving IC50 values ranging between 16 and 70 nM
against both parasite forms. All AIAs presented
superior potency and some, such as DB1868, also
exhibited promising activity as candidates for blood
prophylaxis (Da Silva et al. 2011a, b). The lower
activity of DB1850 may be due to the markedly
different terminal groups (5-membered ring thiazoles
for DB1850 and 6-membered ring pyridine or
pyrimidine for the others). Also, in this study, the
higher activity against BT forms suggests that a range
of variations in the O-alkyl groups (OCH2CF3 to
O-c-pentyl) is tolerated but additional experimental
assays are needed to further evaluate this hypothesis.
Another interesting point is that some of these
AIAs, such as DB745, can be considered fast-acting
compounds. Time-point studies using 10 μgmL−1 of
each compound demonstrated that after 5 min of
incubation, DB745 induced 51% of trypomastigote
lysis whereas the diamidine DB569 and the AIA
DB766 displayed only 16 and 27% of parasite death,
respectively (Da Silva et al. 2011a). However, longer
periods of incubation (60min) resulted in a similar
trypanocidal effect for both AIAs (>96%), while
DB569 resulted in about 50% of parasite lysis
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(Da Silva et al. 2011a). The rapid toxicity of DB745
represents a desirable property for treating acute
parasitic infections such as in Chagas disease,
and further studies should be carried out to explore
the possibility whether different transport mechan-
isms and/or cellular targets may be operating.
Importantly, the different efficacies of some bis-
AIAs (like DB1852 and DB1890) against infective
and non-proliferative bloodstream forms compared
with infective and highly multiplicative (intracellu-
lar) stages may be due to differences in uptake,
mechanisms of action and/or different targets among
these different parasite forms (Da Silva et al.
2011ab47). In fact, striking differences have been
found when the uptake of classical diamidines
(like DB75) and AIAs (like DB766) has been
evaluated on epimastigotes (non-infective but highly
proliferative forms found in blood-sucking vectors)
and bloodstream trypomastigotes: while DB75 (but
not AIAs like DB766) is internalized by trypo-
mastigotes via adenosine/adenine transporter
systems, this is not observed in epimastigotes
(E. Goulart and M. N. C. Soeiro, unpublished data).
These data demonstrated that differences in sensi-
tivity of dicationic compounds among the distinct
T. cruzi forms may be due to (i) different transporters
of diamidines and AIAs according to parasite
evolutive stage and/or (ii) different cellular targets
maybe operating, and thesemust be further explored.
In summary, the excellent antitrypanosomal
efficacy of these novel bis-AIAs against T. cruzi
stimulates further in vivo studies and justifies the
screening of new analogues with the goal of establish-
ing a useful alternative therapy for Chagas disease.
EFFICACY AND SELECTIVITY OF AMIDINES
AND THEIR DERIVATIVES AGAINST
APICOMPLEXAN PARASITES
Apicomplexan parasites cause a wide range of
highly relevant diseases in humans such as malaria,
babesiosis, cryptosporidiosis and toxoplasmosis.
Cryptosporidiosis, babesiosis and toxoplasmosis
also have a high impact on animal health and are
zoonotic diseases. Neosporosis (caused by Neospora
caninum) and besnoitiosis (caused by Besnoitia
besnoiti) are responsible for high economic losses in
farm animal production worldwide (Müller and
Hemphill, 2013). The efficacies and interactions of
amidine compounds with apicomplexans have been
investigated in vitro and, to some extent, also in vivo.
Vector-borne apicomplexans: Plasmodium
and Babesia
The genus Plasmodium causes malaria, and thus
represents a major burden in tropical and subtropical
countries with over 1 million deaths annually.
The clinically most important agent is Plasmodium
falciparum, responsible for malaria tropica, the most
severe form of the disease. While a number of
chemotherapeutically active antimalaria compounds
have been developed and applied in the field,
resistance has been spreading rapidly, and activity
against drug-resistant isolates is a prerequisite for any
lead compound to be developed (Mäser et al. 2012).
In addition, other requirements include excellent oral
bioavailability, low production costs, activity against
all human–pathogenic Plasmodium species, and
ideally cure by a single dose. Pentamidine-analogues
demonstrated antimalarial potency (Bell et al. 1990;
Stead et al. 2001; Bray et al. 2003), but with a low
bioavailability since, as previously described, the
capacity to pass through cellular membranes is
hampered due to ionization of the 2 cationic moieties
at physiological pH. Bakunova et al. (2007) syn-
thesized 43 bisbenzofurans, of which 22 were more
active against P. falciparum than pentamidine, and
7 dications were more effective than artemisinin. A
series of pentamidine congeners bearing the benzo-
furan motif were synthesized and 7 compounds
exhibited in vitro activities against P. falciparum
that were superior to pentamidine (Bakunova et al.
2009). More recently, novel dicationic triazoles were
shown to exhibit promising activities against a
chloroquine-resistant P. falciparum in vitro, with
IC50s ranging from 0·6 nM to 8·39 μM (Bakunov et al.
2010). Eight of these analogues displayed better
antiplasmodial activities in vitro than pentamidine
(IC50=58 nM), and 4,4′-disubstituted diimidazoline
was the most potent one, with an IC50 of 0·6 nM and
an SI of >3 16 667 as determined by in vitro exposure
of L6 rat myoblast cells. In comparison, the most
effective antimalarial drug artemisinin exhibits an
IC50 of 6 nM and a SI of 75 000 (Bakunov et al. 2010).
The genus Babesia comprised approximately 100
described species. Babesiosis has gained increased
interest as a zoonotic disease that is transmitted by
ticks, and affects a wide range of domestic and wild
animals. The major economic impact is on the cattle
industry, but infections also occur in horses, sheep,
goats, pigs and dogs (Müller and Hemphill, 2013).
Babesia bovis and Babesia bigemina are widespread
species affecting cattle in tropical and subtropical
areas, while Babesia divergens infects cattle in Europe
(de Waal and Combrink, 2006). In ticks, the blood
stages of the parasite are ingested during a bloodmeal
and undergo development. Subsequent transmission
of Babesia sporozoites to the host occurs when
infected larvae, nymphs and/or adults feed on their
hosts. Babesia parasites invade and proliferate within
erythrocytes but, in contrast toPlasmodium spp., they
do not develop in a parasitophorous vacuole; they
divide by binary fission (not by schizogeny) and do
not form hemozoin. In Europe, human cases of
babesiosis are mostly caused by B. divergens, while in
North America most human cases involve the rodent
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species Babesia microti (Kjemtrup and Conrad,
2000). Sporadic cases of human babesiosis have also
been identified in Asia, Africa and South America.
The standard drugs used against babesiosis in
animals are atovaquone, imidocarb dipropionate
and diminazene aceturate, of which only imidocarb
acts consistently parasiticidal. In humans, Babesia
infections are treated with combinations of quinine/
clindamycin or atovaquone/azithromycin (Vial and
Gorenflot, 2006). A recent study on the in vitro
activities of novel diamidine compounds against 2
B. divergens strains showed that the most potent
compound, a diphenyl furan, had an outstandingly
low IC50 of 1·5 ngmL
−1 (Nehrbass-Stüdli et al.
2011). Several test compounds, including terphenyls,
benzimidazoles, diphenyl furans, pentamidine
and pentamidine analogues, were effective against
B. microti in mice at a dosage of 12·5 and/or
25mg kg−1 of body weight given by the subcu-
taneous route for 4 days.
Cryptosporidium
Cryptosporidiosis is a cause of diarrheal illness in
immunocompetent hosts such as travellers and
infants attending day care, and represents an impor-
tant opportunistic diarrheal disease in immune-
compromised humans. Cryptosporidiosis occurs
worldwide, and also affects many young farm
mammals as well as cats and dogs, some times with
fatal outcomes. The only drug currently licensed for
the treatment ofCryptosporidium parvum infection in
humans is the nitro-thiazole nitazoxanide, but this
compound is ineffective in immune-compromised
patients (Hemphill et al. 2006), and its use in neonatal
calves has been shown to be accompanied with severe
adverse effects (Schnyder et al. 2009). Compounds
such as halofuginone and decoquinate are reported to
exhibit promising effects and the antibiotic paromo-
mycin is frequently used (Lefay et al. 2001;
Lallemand et al. 2006), but results are variable and
none of these drugs are licensed for the treatment of
cryptosporidiosis, neither in humans nor in food
animals. Pentamidine analogues and aryl furans
were investigated in vitro and in vivo employing
C. parvum-infected Hsd/ICR suckling mice
(Blagburn et al. 1991, 1998a), demonstrating that
oral application of a diaryl furan by gavage at a dosage
of 17·0 and 8·5 mg kg−1 for 5 days resulted in a
reduction in oocyst shedding to 5·1% and 6·4% of
levels, respectively, as compared with non-treated
controls. In a subsequent study (Blagburn et al.
1998b), application of 2,7-diamidinocarbazole dihy-
drochloride at dosages of 10 and 19mg kg−1 resulted
in oocyst outputs of only 0·3 and 0·8% respectively.
In comparison, nitazoxanide applied orally at 100
mg kg−1 yielded a reduced oocyst output of 26%, and
at 150mg kg−1 the residual oocyst output was 4·3%
compared with untreated neonatal mice (Blagburn
et al. 1998b). Paromomycin on the other hand,
applied at 50mg kg−1 exhibited a reduction of oocyst
shedding to 1·2% compared with untreated control
mice. In these experiments, drugs were applied
already 4 h after infection, meaning that parasites
did not establish substantial numbers of develop-
mental stages prior to exposure to the compounds.
Cyst-forming apicomplexans: Toxoplasma gondii,
N. caninum and B. besnoiti
Toxoplasma gondii is the most successful of all
apicomplexan parasites, infecting approximately
30–50% of the human population, and is highly
prevalent in all warm-blooded animals, including
birds. In an immunocompetent host, infection is
normally benign and asymptomatic (Barratt et al.
2010). Clinical problems can arise in individuals
with an immature immune system or in immune-
compromised individuals (e.g. AIDS patients),
where infection can lead to toxoplasmic encephalitis
or even death. Toxoplasmic encephalitis occurs as a
result of the reactivation of brain cysts that encapsu-
late slowly proliferating bradyzoites, which then
undergo bradyzoite-to-tachyzoite stage conversion
(Henriquez et al. 2010). Secondly, congenital tox-
oplasmosis poses a major health risk upon primary
maternal infection during pregnancy, leading to
placental or fetal infection and abortion or damage
of the fetus (Feldman et al. 2010). In addition,
T. gondii is also a highly significant economic and
veterinary medical concern in the livestock industry
(Dubey, 2009). The chemotherapeutic options for
the treatment of toxoplasmosis are limited. Synergis-
tic combination therapies comprised of sulfadiazine/
pyrimethamine, targeting the synthesis and the
reduction of folic acid in tachyzoites, or clindamy-
cin/pyrimethamine, are the most efficient options,
but are prone to adverse effects, and the non-
effectiveness of compounds against bradyzoites that
are enclosed in tissue cysts represents a major
problem (Barratt et al. 2010). The in vitro efficacy
of pentamidine and some pentamidine analogues
against T. gondii has been investigated earlier
(Lindsay et al. 1991) and proliferation-inhibitory
properties were reported at concentrations of around
10 μg ml−1. Leepin et al. (2008) screened 19
dicationic compounds and demonstrated the in vitro
efficacy of 4 derivatives of DB75 (furamidine), which
are built symmetrically with the 2 core structure-
benzene rings being altered. In the diamidine
DB811, this occurs through the addition of 2 chloro
atoms. In the AIA DB750, two hydroxy groups are
added, and in the AIAs DB766 and DB786 iso-
propoxy groups are added at different positions.
These compounds exhibited IC50s between 0·16 and
0·66 μM (0·14–0·5 μgml−1). Neither pentamidine nor
furamidine exhibited meaningful in vitro activity
against T. gondii. Transmission electron microscopy
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demonstrated clear structural damage within drug-
treated parasites, while host cells remained un-
affected. However, since neither of these compounds
exhibited detectable fluorescent properties, it was not
possible to study in which cellular compartments
these compounds localized (Leepin et al. 2008).More
recently, Kropf et al. (2012) re-investigated the in
vitro characteristics of the most promising com-
pound, DB750, in the virulent T. gondii RH strain
(genotype 1) and an avirulent strain, Me49 (genotype
2). Three-day-growth assays showed that DB750
inhibited the proliferation of tachyzoites of both
strains with an IC50 of 0·11 and 0·13 μM, respectively,
but the drug did not affect extracellular parasites.
Thus no inhibition of host cell invasion upon DB750
treatment was observed. In addition, fibroblast
monolayers that were treated with 1 μM DB750 for
12 h prior to infection were subsequently infected,
and further culture of these infected fibroblasts in the
absence of the DB750 for 3 days resulted in a
pronounced inhibition of parasite proliferation,
indicating that DB750 was actively taken up and
accumulated within the host cells, causing a memory
effect. However, upon continuous exposure to
DB750 for 5–6 days, T. gondii tachyzoites adapted
to the drug and resumed proliferation in the presence
of a DB750 concentration of up to 1·2 μM. This made
it possible to generate DB750-adapted T. gondii
strains. Kropf et al. (2012) also screened another set
of compounds comprised of 10 bis-AIAs, 6 diamidines,
15 newly generatedmono-arylimidamides, and 10 di-
guanidino analogues against T. gondii, and the AIA
DB745, exhibiting an IC50 of 0·03 μM and most
favourable selective toxicity was chosen for further
studies. In DB745, each of the 2 phenyl rings is
substituted by an O-ethyl-moiety. DB745 also
efficiently inhibited the proliferation of DB750-
adapted T. gondii (IC50=0·07 μM) and, in contrast
to DB750, DB745 had a profound toxic effect on
extracellular T. gondii tachyzoites. Adaptation (or
resistance) of T. gondii to DB745 (up to a concen-
tration of 0·46 μM)was difficult to achieve and feasible
only by stepwise increasing the drug concentration
over a period of 110 days. Overall, these investi-
gations illustrated the astonishing capacity of
T. gondii tachyzoites to adapt to environmental
changes, at least under in vitro conditions, and open
the door to further investigations on the mechanisms
of action of these compounds in T. gondii (Kropf
et al. 2012).
Neospora caninum is closely related toT. gondii, but
infection in humans has not been reported, and the
parasite owes his importance due to the fact that it
represents one of the most important causes of
abortion in cattle worldwide (Monney et al. 2011).
Neospora isolates with different virulence have been
obtained, such as Nc-Liverpool representing a highly
virulent isolate, and Nc-1, which is an isolate with
lower virulence. Screening for anti-Neospora activity
involved the same compounds as for T. gondii, and
not surprisingly, DB750 and DB745 also emerged as
the most effective ones, albeit with differences in
terms of IC50 values (e.g. IC50 of DB745=80 nM for
N. caninum and 30 nM for T. gondii (RH) tachyzoites
(Kropf et al. 2012; Schorer et al. 2012). As
for T. gondii, DB750 inhibited proliferation of
N. caninum tachyzoites, but was not effective against
extracellular parasites, while DB745 treatment re-
sulted in inhibition of host cell invasion. A detailed
TEM analysis of the effects of DB745 on intracellular
N. caninum tachyzoites revealed (Fig. 6) that (i) the
integrity of the nuclear membrane was altered in
the drug-treated parasites and (ii) most nuclei of
drug-treated parasites were devoid of a discernible
nucleolus (Fig. 6C). This suggested that DB745
could interfere in the maintenance of the nuclear
membrane integrity, possibly interfere in lipid
metabolism, and/or in transcriptional activity of
these parasites, the latter of which would be
potentially in agreement with the postulated mode
of action involving DNA-binding. In addition,
DB745 treatment resulted in tachyzoites that were
fused together at their outer membranes (Fig. 6D).
Closer inspection of the contact sites at higher
magnification revealed that these were tachyzoites
caught in the process of endodyogeny, with the inner
membrane layer surrounding both daughter cells and
the inner membrane layer either fully present or
partially interrupted (Fig. 6E; Schorer et al. 2012).
These observations indicated that DB745 could
potentially interfere in the formation/metabolism of
membranous structures within these parasites. In this
context it is interesting to note that a recent study by
Ando et al. (2012) demonstrated that treatment with
related compounds such as diminazene, pentamidine
and 4′6′-diamidino-2-phenylindole (DAPI) in-
creased the permeability of bacterial outer mem-
branes.
Long-term growth assays in the presence ofDB745
revealed that the drug had a parasiticidal action
against the more virulent Nc-Liverpool isolate, while
Nc-1 tachyzoites could adapt to increased concen-
trations of DB745 (up to 0·30 μM within a timeframe
of 69 days). In vivo studies were performed in mice
that were experimentally infected with the Nc-1
isolate, showing that both DB745 and DB750
treatment by intraperitoneal injection of compounds
at 2 mg kg−1 for 14 days resulted in a significantly
increased number of survivors and significantly
decreased cerebral parasite burden compared with
non-treated mice (Debache et al. 2011; Schorer et al.
2012). In these experiments, treatments were started
14 days after infection, thus the parasites had already
reached the CNS, and thus these compounds most
likely were effective in crossing the blood–brain
barrier. However, oral application of these two
compounds was ineffective (unpublished findings).
These initial in vivo results are promising, and
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point out the therapeutic potential of theAIAsDB745
and DB750, and the class of dicationic compounds
as awhole, for the treatment ofN. caninum infections.
From the practical point of view on neosporosis
in cattle, treatment of congenitally infected calves
right after birth could potentially give rise to
pathogen-free offspring (Härdi et al. 2006), provided
an effective compound can be identified.
Dicationic compounds were also evaluated with
respect to their activity against B. besnoiti tachyzoites
grown in Vero cells. Besnoitia besnoiti is most closely
related to N. caninum and T. gondii. The life cycle of
B. besnoiti remains mysterious and its definitive
host is unknown. Infection assays have shown that
B. besnoiti infects a variety of potential hosts, but
persists only in voles (Basso et al. 2011). Besnoitia
besnoiti is transmitted to cattle by haematophagous
insects and causes a systemic disease which, during
the acute phase with a high parasitaemia, may be
associated with fever and fever-associated signs,
including abortion. Subsequently, in the chronic
stage, the parasite shows a high tropism to the skin,
leading to dramatic thickening, hardening and fold-
ing, always accompanied by hyperkeratosis, hyper-
pigmentation and alopecia, and a decrease of milk
production is commonly observed. Furthermore,
Besnoitia infection in bulls can cause irreversible
aspermy and sterility (Jacquiet et al. 2010). The
rapidly proliferating B. besnoiti tachyzoites can be
cultivated as described for N. caninum and T. gondii.
By employing such cultures, drug-screening assays
have been performed in order to identify compounds
of potential interest for chemotherapeutic treatment,
including AIAs (Cortes et al. 2011). Results were
different compared with T. gondii and N. caninum.
DB750 (IC50=0·59 μM) acted only parasitostatic after
14 days of treatment at 1·7 μM, while DB811
(IC50=0·079 μM) was highly effective, and had a
parasiticidal action in vitro (Cortes et al. 2011). Thus,
B. besnoiti is susceptible to other dicationic com-
pounds, implying that possibly the target(s) in
B. besnoiti affected by these compounds are different
or at least altered compared with T. gondii and
N. caninum. However, the biggest challenge for drug
development against these cyst-forming apicomplex-
ans is still to generate compounds that affect the
respective bradyzoite stages encapsulated within
tissue cysts.
CONCLUDING REMARKS
In conclusion, amidine-containing compounds rep-
resent a versatile class of drugs, with a great potential
for the further development of novel chemotherapies
against intracellular parasitic protozoa. The hall-
marks of the more recently generated compounds are
oral bioavailability, metabolic stability, and an
increased capacity to pass through biological mem-
branes that makes them uniquely suited to reach
parasites that reside and hide within host cells. Some
structural modifications also aid in crossing the
blood–brain barrier, which is relevant for infections
that also affect the CNS. The use of in vitro culture
systems has been instrumental for preliminary
efficacy assessments and allowed identification of
compounds with IC50s in the low nanomolar range,
but care must be taken in the respective assessments,
since the findings obtained in vitro cannot always be
translated into high efficacy in vivo. Pentamidine and
many of its derivatives have been designed to bind to
the minor groove of DNA, and are found either
within the kinetoplast in trypanosomatids or the
nucleus in other parasites, but most likely other
cellular targets may also be involved. Importantly,
the higher potency of AIAs against intracellular
agents (like T. cruzi and Leishmania) compared with
classical dicationic amidines justify further screening
studies also against other parasites like extra-erythro-
cytic Plasmodium species. The fact that the amidines
act against a variety of species living an intracellular
lifestyle, and that some are effective in many species
while others affect only one, also argues for multiple
modes of action. In the future, it will be important to
understand the alterations induced by these drugs not
only on morphology and ultrastructure, but also on
themolecular level. Itwill be important tounderstand
the molecular changes in gene expression, and to
elucidate how these compounds affect themetabolism
of their targeted parasites as well as mammalian host
cells.Thiswill help tounderstand theirmodeof action
and to identify the relevant drug targets, information
that can be exploited to generate novel and more
effective compounds against parasitic diseases.
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